1. Home
  2. CNXC vs BRVE Comparison

CNXC vs BRVE Comparison

Compare CNXC & BRVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Concentrix Corporation

CNXC

Concentrix Corporation

N/A

Current Price

$29.47

Market Cap

2.0B

Sector

Technology

ML Signal

N/A

Logo Braveheart Bio Inc. Common Stock

BRVE

Braveheart Bio Inc. Common Stock

N/A

Current Price

$20.36

Market Cap

1.8B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CNXC
BRVE
Founded
1991
2024
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.8B
IPO Year
2020
2026

Fundamental Metrics

Financial Performance
Metric
CNXC
BRVE
Price
$29.47
$20.36
Analyst Decision
Buy
Strong Buy
Analyst Count
5
5
Target Price
$32.60
★ $45.50
AVG Volume (30 Days)
★ 802.8K
473.2K
Earning Date
09-29-2026
11-10-2026
Dividend Yield
★ 5.18%
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $9,825,771,000.00
N/A
Revenue This Year
$0.26
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 2.15
N/A
52 Week Low
$19.12
$16.70
52 Week High
$44.78
$32.00

Technical Indicators

Market Signals
Indicator
CNXC
BRVE
Relative Strength Index (RSI) 46.02 49.49
Support Level $28.51 $17.52
Resistance Level $30.75 $22.04
Average True Range (ATR) 1.90 1.76
MACD -0.41 0.07
Stochastic Oscillator 17.10 67.28

Price Performance

Historical Comparison
CNXC
BRVE

About CNXC Concentrix Corporation

Concentrix Corp is a technology and services company. It designs, implements, and manages end-to-end solutions, including customer experience process optimization, technology development and design engineering, front- and back-office automation, analytics, and business transformation services. The company serves clients across multiple industry verticals, helping them manage customer engagement and operational processes throughout the customer lifecycle. The company operates in a single operating segment. It generates revenue through the provision of technology and services under contractual arrangements. Geographically, the company generates the maximum revenue from the Philippines and the rest from India, the United States, Great Britain, Germany, Canada and Other countries.

About BRVE Braveheart Bio Inc. Common Stock

Braveheart Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics to treat hypertrophic cardiomyopathy (HCM) and other cardiovascular diseases. Its flagship product candidate, BHB-1893, is an oral small-molecule cardiac myosin inhibitor being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM).

Share on Social Networks: